ArticleOncology letters2025

Application value and safety of trilaciclib in first-line chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer: A real-world study.

Yanping Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.